Introduction Anaplastic lymphoma kinase (ALK) rearranged non-small cell lung carcinoma (NSCLC) has emerged as a distinct entity with growing number of potent ALK tyrosine kinase inhibitors (TKIs). Despite showing durable responses and promising survival rates. resistance to these ensue. This is the largest series of repeat biopsies from patients of ALK-positive NSCLC progressing on AL... https://www.popularfilm.blog/